Table 2 Summary of patients’ requests for funding of Ranibizumab (source: authors’ analysis of data from Clalit Mushlams’ cohort of members funding applications, March 1, 2012 to December 31, 2015)
Previously approved Tx | Pt applying | Pt dropped out from previous Tx | Total No′ of applications | Mean No′ of applications per Pt | Pt approved w/o further scrutiny | Pt approved after repeated application | Pt not receiving funding | Total Pt approved for funding |
|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | |||||
0 | 5642 | – | 6452 | 1.1 | 4740 (84.0%) | 614 (10.9%) | 288 (5.1%) | 5354 (94.9%) |
1 | 3325 | 2029 | 4143 | 1.2 | 2519 (75.8%) | 588 (17.7%) | 218 (6.5%) | 3107 (93.5%) |
2 | 2005 | 1102 | 2454 | 1.2 | 1556 (77.6%) | 321 (16.0%) | 128 (6.4%) | 1877 (93.6%) |
3 | 1233 | 644 | 1478 | 1.2 | 986 (80.0%) | 184 (14.9%) | 63 (5.1%) | 1170 (94.9%) |
4 | 791 | 379 | 963 | 1.2 | 631 (79.8%) | 121 (15.3%) | 39 (4.9%) | 752 (95.1%) |
5 | 478 | 274 | 560 | 1.2 | 393 (82.2%) | 58 (12.1%) | 27 (5/7%) | 451 (94.3%) |
6 | 273 | 178 | 329 | 1.2 | 208 (76.2%) | 42 (15.4%) | 23 (8.4%) | 250 (91.6%) |
7 | 160 | 90 | 191 | 1.2 | 126 (78.8%) | 23 (14.4%) | 11 (6.8%) | 149 (93.2%) |
8 | 86 | 63 | 107 | 1.2 | 63 (73.3%) | 15 (17.4%) | 8 (9.3%) | 78 (90.7%) |
9 | 46 | 32 | 48 | 1 | 44 (95.7%) | 2 (4.3%) | 0 (0%) | 46 (100.0%) |
10 | 22 | 24 | 24 | 1.1 | 19 (86.4%) | 2 (9.1%) | 1 (4.5%) | 21 (95.5%) |
11 | 12 | 9 | 14 | 1.2 | 9 (75.0%) | 2 (16.7%) | 1 (8.3%) | 11 (91.7%) |
12 | 6 | 5 | 7 | 1.2 | 4 (66.7%) | 1 (16.7%) | 1 (6.6%) | 5 (83.4%) |
13 | 3 | 2 | 4 | 1.3 | 2 (66.7%) | 1 (33.3%) | 0 (0%) | 3 (100.0%) |
14 | 2 | 1 | 2 | 1 | 2 (100.0%) | 0 (0%) | 0 (0%) | 2 (100.0%) |
15 | 1 | 1 | 1 | 1 | 1 (100.0%) | 0 (0%) | 0 (0%) | 1 (100.0%) |
16 | 1 | 0 | 1 | 1 | 1 (100.0%) | 1 (100.0%) | 0 (0%) | 1 (100.0%) |
Total | 14,086 | 4833 | 16,778 | 3 | 11,303 (80.2%) | 1975 (14.02%) | 808 (5.7%) | 13,278 (94.3%) |